Introduction/Background Borderline ovarian tumors (BOT) are defined as atypical epithelial proliferation without histopathological stromal invasion. Tumors with low malignancy potential, tend to be limited to ovary and CA 125 is not elevated in majority of patients. In this study, we aim to investigate CA 125 levels in patients with BOT.

Methodology 56 patients, final pathologies were reported as BOT were included. Age, menapausal status, histological type and stage of the tumor were evaluated and compared with CA 125 levels, retrospectively.

Results The mean age of the patients was 42.9 (19–84) and 66.1% of the patients were premenapausal. Serous histology was detected in 67.9% of the patients, the remaining histology was musinous, brenner or mix type. 83.9% of the patients disease was limited to the ovary. 57.1% of the patients Ca 125 levels were above normal range. Mean level of CA 125 was 227.2 U/ml, ranged between 3–5668 U/ml (table 1). There was positive corelation between CA 125 levels and premenapausal status, serous histology and extraovarian spread (table 2).

Conclusion CA 125 is especially used in monitoring the response to treatment in invasive epithelial ovarian cancer. In early stage disease and in premenopausal women its benefits are limited. It is reported that there isn’t a significant increase in CA 125 in BOT. However, in our study, elevation in CA 125 level was found in a significant number of patients and it was related to stage and serous histology, and higher levels were detected in the majority of premenopausal patients. This suggests that detection of CA 125 levels in BOT may have prognostic significance in addition to assisting the diagnosis.

Disclosure Nothing to disclose.